Skip to search formSkip to main contentSkip to account menu

NCX 1015

Known as: NCX-1015, NCX1015 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Background The addition of a nitric oxide (NO)‐releasing moiety to prednisolone was shown to enhance the anti‐inflammatory… 
Review
2008
Review
2008
EDITORIAL EXPRESSION OF CONCERN. PNAS is publishing an Editorial Expression of Concern regarding the following three articles: (i… 
2004
2004
Daily administration of prednisolone, but not the derivative NCX-1015 (or prednisolone 21-[4′-nitrooxymethyl]benzoate), to rats… 
Highly Cited
2003
Highly Cited
2003
It has recently emerged that posttranslational modification of proteins via nitration of tyrosine residues can alter their… 
2003
2003
Derivatization of nonsteroidal anti‐inflammatory drugs, such that they release nitric oxide (NO) in small amounts, has been shown… 
Highly Cited
2002
Highly Cited
2002
Here, we describe the improved antiarthritic properties of a nitric oxide-releasing derivative of prednisolone that includes a… 
Highly Cited
2002
Highly Cited
2002
NCX-1015 is a nitric oxide (NO)-releasing derivative of prednisolone. In this study we show NCX-1015 protects mice against the S… 
Highly Cited
2000
Highly Cited
2000
Anti‐inflammatory effects of a novel derivative of the glucocorticoid prednisolone were investigated. NCX‐1015 (prednisolone 21…